newsfilter
← Latest News
GlobeNewswire·

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) announced that an abstract from its Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer has been accepted for presentation at the 2026 ASCO Annual Meeting.
  • The accepted abstract details a pharmacokinetic & pharmacodynamic sub-study examining intra-arterial gemcitabine (IAG) delivered via the RenovoCath device versus intravenous gemcitabine.
  • The study explores IAG's potential to reduce systemic chemotherapy levels, increase inactive metabolite levels, and correlate these metabolite levels with the CA 19-9 biomarker.
  • Dr. Ramtin Agah, Executive Chairman & Chief Medical Officer, stated the study provides insights into optimizing drug distribution while potentially reducing systemic toxicity.
  • The 2026 ASCO Annual Meeting will take place May 29 – June 2, 2026, in Chicago, Illinois, with the abstract online publication scheduled for May 21, 2026, at 5:00 P.M. ET (Publication Number: E16463).
  • RenovoRx reported approximately $1.1 million in RenovoCath sales during its first full year of commercialization, with expanding orders from high-volume National Cancer Institute-designated centers.
  • The IAG combination product candidate is under investigation by the FDA via a U.S. investigational new drug application & holds Orphan Drug Designation for pancreatic cancer & bile duct cancer.
  • RenovoRx is actively exploring further revenue-generating activities for its TAMP technology, either independently or through medical device commercial partners.